SEHK:1952Biotechs
Everest Medicines (SEHK:1952) Valuation Spotlight as Leadership Transition Signals Strategic Shift
Everest Medicines (SEHK:1952) is set for a transition at the top, as Wei Fu steps down as chairman to focus on other commitments. Yifang Wu, a seasoned veteran from Fosun Pharma, will take the helm starting October 10, 2025.
See our latest analysis for Everest Medicines.
Investors seem to be weighing Everest Medicines’ leadership shake-up against its strong recent momentum, with the share price up 4% in the past day and 7% year-to-date. Despite short-term volatility, the company's one-year...